Relationship between Apolipoproteins, Lipoprotein (a) and conventional cholesterol and lipids with insulin resistance.
DOI:
https://doi.org/10.29309/TPMJ/2022.29.06.6590Keywords:
Apo-A1, Apo-B, Fasting Triglycerides, HOMAIR, HDL-Cholesterol, Lipoprotein (A), LDL-Cholesterol, Total CholesterolAbstract
Objective: To evaluate Apo-A1, Apo-B and Lipoprotein (a) and conventional lipid profile parameters among subjects with high and low insulin resistance groups. Study Design: Cross Sectional study. Setting: Naval Hospital, Islamabad. Period: 2018 to 2020. Material & Methods: To include 164 subjects after several exclusions. We carried out conventional lipid indices along with serum insulin, Apo-A1, Apo-B and Lp (a) on these subjects after formal permission. We calculated insulin resistance by using the the HOMAIR index. Results: Male population demonstrated higher Apo-B [(Male: 66.44+21.75) vs (Female: 60.84+19.96), p=0.095], triglycerides [(Male: 2.29+1.35) vs (Female: 1.84+0.93), p=0.014] while male showed lower Lp (a) [(Male: 126.13+9.15) vs (Female:16.60+9.39), p=0.095] and Apo-A1. 126.13+21.97) vs (Female: 135.34 +25.24), p=0.017]. Apo-A1 showed highest but still weak positive correlation with HDLc, while Apo-B demonstrated higher positive correlation with total correlation, triglycerides, LDLc, non-HDLc and Lp (a). Among comparison between high and low insulin resistance groups, we could only demonstrate significant differences between triglycerides [Low insulin resistance group: 1.94+1.15 vs High insulin resistance group: 2.41+1.29, p=0.019] and Apo-A1 [Low insulin resistance group: 132.54+23.16 vs High insulin resistance group: 124.91+24.17, p=0.050]. Conclusion: Apo-B demonstrated higher positive correlation with total correlation, triglycerides, LDLc, non-HDLc and Lp (a). There were significant differences for triglycerides and Apo-A1 between insulin resistance groups. Female gender and higher insulin resistance groups demonstrated higher Apo-A1 levels.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 The Professional Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.